Consideration of a 2-phase framework to obesity management (ie, active weight-loss phase, followed by maintenance of weight-loss phase) allows a potential move away from the current “full-dose GLP-1/IM or nothing” approach to a more personalized weight maintenance approach. The gene discussed is GCG; the disease is obesity disorder.